{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:24:19Z","timestamp":1769207059350,"version":"3.49.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"<jats:p>Hormones have been shown to affect the pathophysiology of rosacea, however, the prevalence of rosacea in transgender and gender diverse (TGD) patients on gender affirming hormone therapy (GAHT) has never been studied. Our retrospective cohort study showed a significantly decreased prevalence TGD patients on feminizing GAHT compared to cisgender men, women, and TGD not on GAHT. Our results suggest that estrogen and\/or anti-androgenetic agents may play a protective role in the development or course of rosacea.<\/jats:p>","DOI":"10.1093\/bjd\/ljac041","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:18:20Z","timestamp":1674224300000},"page":"304-306","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of rosacea in transgender and gender-diverse populations: a retrospective cohort study"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3910-9287","authenticated-orcid":false,"given":"Jessika","family":"Sanz","sequence":"first","affiliation":[{"name":"The Fenway Institute, Fenway Health , Boston, MA , USA"},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"New York Institute College of Osteopathic Medicine , Jonesboro, AR , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia L","family":"Gao","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine & Health Sciences , Washington, DC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana S","family":"King","sequence":"additional","affiliation":[{"name":"The Fenway Institute, Fenway Health , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-4078","authenticated-orcid":false,"given":"Anna M","family":"Modest","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, USA and"},{"name":"Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica D","family":"Dommasch","sequence":"additional","affiliation":[{"name":"The Fenway Institute, Fenway Health , Boston, MA , USA"},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"2023100520313923200_ljac041-B1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1440-0960.1971.tb00003.x","article-title":"Effect of oral inhibitors of ovulation in treatment of rosacea and dermatitis perioralis in women","volume":"12","author":"Spirov","year":"1971","journal-title":"Australas J Dermatol"},{"key":"2023100520313923200_ljac041-B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1346-8138.1992.tb03227.x","article-title":"Oral spironolactone therapy in male patients with rosacea","volume":"19","author":"Aizawa","year":"1992","journal-title":"J Dermatol"},{"key":"2023100520313923200_ljac041-B3","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1038\/jid.2013.186","article-title":"Spironolactone may reduce the risk of incident rosacea","volume":"133","author":"Spoendlin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2023100520313923200_ljac041-B4","first-page":"59","article-title":"Experiences in dermatology with various contraceptives containing gestagen","volume":"22","author":"Vankos","year":"1972","journal-title":"Gyogyszereink"},{"key":"2023100520313923200_ljac041-B5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.18773\/austprescr.2019.003","article-title":"Prescribing for transgender patients","volume":"42","author":"Tomlins","year":"2019","journal-title":"Aust Prescr"},{"key":"2023100520313923200_ljac041-B6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/bjc.2015.217","article-title":"Personal history of rosacea and risk of incident cancer among women in the US","volume":"113","author":"Li","year":"2015","journal-title":"Br J Cancer"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac041\/48343361\/ljac041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/304\/51903044\/ljac041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/304\/51903044\/ljac041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:56:28Z","timestamp":1696539388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/2\/304\/6812672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":6,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,9]]},"published-print":{"date-parts":[[2023,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac041","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,11,9]]}}}